Analyst firms · Barclays · SHC
Barclays SHC price target and rating history
Sotera Health Company (SHC) · Health Care
Barclays rates Sotera Health Company (SHC) Overweight with a $22 price target, as of its latest action on Jan 11, 2023. It has published 5 rating actions on SHC since July 2021, including 1 upgrade and 2 downgrades. Across 4 firms with a SHC price target in the last 12 months, the median target is $22.
- Current rating
- Overweight
- Price target
- $22
- Median target, all firms
- $22
- Actions on SHC
- 5
Barclays price target on SHC
Every Barclays rating on SHC
- Jan 11, 2023
- Nov 15, 2022
- Mar 2, 2022
- Aug 13, 2021
- Jul 13, 2021
How other firms rate SHC
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Goldman Sachs | Buy | $20 | Jun 5, 2026 |
| Piper Sandler | Overweight | $24 | Jan 9, 2026 |
| RBC Capital Markets | Outperform | $24 | Jan 9, 2026 |
| William Blair | Outperform | Dec 18, 2025 | |
| BMO Capital Markets | Outperform | $19 | Nov 13, 2025 |
Questions about Barclays and SHC
- What is Barclays's price target for SHC?
- Barclays's latest stated price target for Sotera Health Company (SHC) is $22, from its action on Jan 11, 2023.
- What is Barclays's rating on SHC?
- Barclays rates SHC Overweight, a bullish rating, as of Jan 11, 2023.
- When did Barclays last change its view on SHC?
- On Jan 11, 2023, Barclays upgrades to Overweight from Underweight, price target $6 to $22.
- How does Barclays's SHC target compare with other analysts?
- Across 4 firms with a SHC price target in the last 12 months, the median target is $22.
More SHC rating histories
All Barclays ratingsSHC news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.